Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie obserwacyjne oceniające skuteczność i bezpieczeństwo połączenia awelumabu i aksytynibu u uczestników z aRCC (AVION)

20 maja 2026 zaktualizowane przez: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Rzeczywista ocena skuteczności i bezpieczeństwa stosowania awelumabu (BAVENCIO®) + aksytynibu (INLYTA®) u pacjentów z aRCC w wielu krajach UE (AVION)

Głównym celem tego badania jest poszerzenie wiedzy na temat skuteczności dożylnego wlewu awelumabu w skojarzeniu z aksytynibem jako terapii pierwszego rzutu u uczestników z zaawansowanym rakiem nerkowokomórkowym (aRCC) oprócz bezpieczeństwa i tolerancji w rutynowych warunkach codziennego praktyka kliniczna.

Przegląd badań

Status

Zakończony

Warunki

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

105

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Belgia
      • Bonheiden, Belgia
        • Imelda Ziekenhuis
      • Brasschaat, Belgia
        • AZ Klina
      • Bruges, Belgia
        • AZ Sint-Jan
  • Grecja
      • Athens, Grecja
        • Gen. Hos. "Alexandra"
      • Athens, Grecja
        • General Hospital of Athens G.Gennimatas
      • Athens, Grecja
        • Henry Dunant Hospital Center
      • Athens, Grecja
        • University Hospital of Athens Sotiria
      • Attiki, Grecja
        • Attikon Hospital
      • Chaïdári, Grecja
        • Attikon
      • Heraklion, Grecja
        • General Hospital "Venizelio"
      • Ioannina, Grecja
        • University Hospital of Ioannina
      • Kavala, Grecja
        • Kavala General Hospital
      • Larissa, Grecja
        • University Hospital of Larissa
      • Piraeus, Grecja
        • Metaxa Hospital
      • Piraeus, Grecja
        • Metropolitan Hospital Greece
      • Pátrai, Grecja
        • General Hospital of Patras "o Agios Andreas"
      • Thessaloniki, Grecja
        • Papageorgiou Hospital
      • Thessaloniki, Grecja
        • Agios Loukas Hospital
      • Thessaloniki, Grecja
        • Bioclinic (GRC)
      • Thessaloniki, Grecja
        • Saint Luke Hospital
  • Niemcy
      • Amberg, Niemcy
        • Klinikum St. Marien Amberg
      • Aschaffenburg, Niemcy
        • Klinikum Aschaffenburg Medizinische Klinik
      • Berlin, Niemcy
        • Zentrum für urologische Onkologie
      • Biberach an der Riss, Niemcy
        • Biberach
      • Bielefeld, Niemcy
        • Evangelisches Klinikum Bethel
      • Bielefeld, Niemcy
        • Evangelisches Krankenhaus Bielefeld
      • Braunschweig, Niemcy
        • Urologie im Schlosscarree
      • Deggendorf, Niemcy
        • Donauisar Klinikum Deggendorf
      • Dresden, Niemcy
        • Urologische Gemeinschaftspraxis
      • Eisenach, Niemcy
        • St. Georg Klinikum Eisenach gGmbH
      • Erlangen, Niemcy
        • Universitätsklinikum Erlangen
      • Essen, Niemcy
        • Universitaetsklinikum Essen Uroonkologie
      • Friedrichshafen, Niemcy
        • Klinikum Friedrichshafen GmbH daVinci® -Zentrum Bodensee
      • Fürth, Niemcy
        • Onkologische GP Dres. Wilke/Wagner/Petzoldt
      • Fürth, Niemcy
        • Onkologische SP Praxis Fürth
      • Goslar, Niemcy
        • MVZ Onkologische Kooperation Harz GbR
      • Halberstadt, Niemcy
        • Praxis Dr. Maas
      • Hamburg, Niemcy
        • Universitätsklinikum Hamburg-Eppendorf
      • Hanover, Niemcy
        • Medizinische Hochschule Hannover
      • Hanover, Niemcy
        • Vinzenzkrankenhaus Hannover
      • Heinsberg, Niemcy
        • Praxis Kretz
      • Jena, Niemcy
        • Universitätskinderklinik Jena
      • L.-Eisleben, Niemcy
        • Urologische Praxis Dr. Ralf Eckert
      • Luckenwalde, Niemcy
        • Urologische Praxis Dipl.-Med. Susanne Kloß
      • Lübeck, Niemcy
        • Universitatsklinik Schleswig-Holstein
      • Magdeburg, Niemcy
        • Schwerpunktpraxis für Hämatologie und Onkologie
      • Minden, Niemcy
        • Johannes Wesling Klinikum Minden der Mühlenkreiskliniken (AöR)
      • Münster, Niemcy
        • University of Munster
      • Münster, Niemcy
        • Uniklinikum Münster
      • Osnabrück, Niemcy
        • Marienhospital Osnabrück - Standort Natruper Holz
      • Osnabrück, Niemcy
        • Paracelsus Klinik Osnabrück
      • Osnabrück, Niemcy
        • Klinikum Osnabrück GmbH
      • Ostfildren, Niemcy
        • medius Klinik Ostfildern-Ruit
      • Rostock, Niemcy
        • Wissenschaftskontor Nord GmbH & Co. KG
      • Rüsselsheim am Main, Niemcy
        • GPR Klinikum Rüsselsheimg GmbH
      • Sigmaringen, Niemcy
        • SRH Kliniken Landkreis Sigmaringen (DEU)
      • Stolberg, Niemcy
        • Hämatologie und Onkologie Stolberg
      • Troisdorf, Niemcy
        • Praxis Troisdorf
      • Westerstede, Niemcy
        • Medizinische Studiengesellschaft Nord-West GmbH
      • Wetzlar, Niemcy
        • Lahn Dill Kliniken GmbH
  • Rosja
      • Irkutsk, Rosja
        • Regional Oncology Dispensary - Irkutsk

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Uczestnicy z potwierdzoną diagnozą zaawansowanego RCC będą obserwowani w tym badaniu.

Opis

Kryteria przyjęcia:

  • Uczestnicy ze statusem sprawności Eastern Cooperative Oncology Group (ECOG) 0, 1 lub 2
  • Uczestnicy z histologicznie potwierdzonym rozpoznaniem RCC o dowolnym pochodzeniu histologicznym
  • Uczestnicy z lokalnie zaawansowaną/przerzutową chorobą (tj. nowo zdiagnozowanym RCC stopnia 4 według Amerykańskiego Wspólnego Komitetu ds. Raka) lub z chorobą nawracającą
  • Uczestnicy otrzymali 1 lub 2 cykle leczenia awelumabem plus aksytynibem jako leczenie pierwszego rzutu zgodnie z zatwierdzoną charakterystyką produktu leczniczego (ChPL)
  • Uczestnicy chętni do podpisania pisemnego formularza świadomej zgody (ICF) na udział w tym badaniu

Kryteria wyłączenia:

  • Uczestnicy z przeciwwskazaniami do stosowania awelumabu lub aksytynibu zgodnie z zatwierdzoną ChPL
  • Uczestnicy, którzy brali udział w jakimkolwiek interwencyjnym badaniu klinicznym leku lub wyrobu w ciągu 28 dni przed rozpoczęciem stosowania awelumabu i aksytynibu

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Awelumab + Aksytynib
W tym badaniu nie będzie żadnych interwencji specyficznych dla badania. Uczestnicy z zaawansowanym RCC otrzymujący 800 miligramów (mg) awelumabu dożylnie co 2 tygodnie w połączeniu z 5 mg aksytynibu doustnie dwa razy dziennie zgodnie z warunkami pozwolenia na dopuszczenie do obrotu w terapii pierwszego rzutu zgodnie z aktualną praktyką kliniczną będą obserwowani w tym badaniu przez 24 miesiące.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Overall Survival Rate
Ramy czasowe: At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])
Overall survival rate was defined as the percentage of participants who are alive at 12 months after the index date. Percentage of participants alive at the time of outcome assessment (12 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Overall Survival Rate
Ramy czasowe: At 24 months after index date (baseline visit as reported in the eCRF)
Overall survival rate was defined as the percentage of participants who are alive at 24 months after the index date. Percentage of participants alive at the time of outcome assessment (24 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 24 months after index date (baseline visit as reported in the eCRF)
Duration of Overall Survival
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Duration of overall survival is defined as the time from index date to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Objective Response Rate (ORR) Assessed by Investigator up to 24 Months After the Index Date
Ramy czasowe: up to 24 months after the index date (baseline visit as reported in the eCRF)
Objective response rate was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) as best overall response up to 24 months after the index date. CR: Disappearance of all target and non-target lesions. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of their diameters, and no unequivocal progression of non-target lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease Control Rate (DCR) Assessed by Investigator up to 24 Months After the Index Date
Ramy czasowe: up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease control rate is defined as the percentage of participants with objective response (complete response [CR] or partial response [PR] or stable disease [SD]) as best overall response up to 24 months after the index date. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Ramy czasowe: up to 24 months after the index date (baseline visit as reported in the eCRF)
DoR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 Assessed by Investigator
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS time was defined as the time from index date to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered PD. The tumor response was determined according to RECIST version 1.1 and assessed by the investigator. PFS was calculated based on KM method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Progression-free Survival 2 (PFS2) According to RECIST Version 1.1 Assessed by Investigator
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS2 was defined as time interval from the index date to the date of disease progression on second-line treatment or death from any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The tumor response will be determined according to RECIST version 1.1 and assessed by the investigator. PFS2 was calculated based on Kaplan Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Change From Baseline in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Total Score
Ramy czasowe: Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
NCCN-FACT FKSI-19, a validated, disease-specific questionnaire for RCC. It includes 19 items across four domains, Disease-Related Symptoms-Physical (DRS-P), Disease-Related Symptoms-Emotional (DRS-E), Treatment Side Effects (TSE), and Functional Wellbeing (FWB), based on symptoms experienced over past 7 days. Responses were recorded on 5-point Likert scale (0 = not at all to 4 = very much), yielding a total score from 0 to 76, higher scores reflecting better quality of life. A negative mean change in score indicated worsening condition. Domain score ranges and directionality: DRS-P: 0-48, higher scores = fewer physical symptoms; DRS-E: 0-4, higher = fewer emotional symptoms; TSE: 0-12, higher = more severe side effects; FWB: 0-12, higher = better functional wellbeing. As per NCCN-FACT FKSI-19 scoring guidelines, the total Health-related quality of life (HRQoL) score (range 0-76) was calculated as sum of single items scores multiplied by 19 and divided by the number of items completed.
Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs, TEAEs Leading to Permanent Treatment Discontinuation and TEAEs Leading to Death According to Medical Dictionary for Regulatory Activities (MedDRA)
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Number of Participants With Adverse Events Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Severity of TEAEs were evaluated using the NCI-CTCAE version 5.0. The grade are as follows: grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE. Number of participants with TEAEs grade greater than or equal to (>=) 3 were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Time to Therapy Discontinuation Due to AE Greater Than or Equal to (>=) Grade-3
Ramy czasowe: From the index date (baseline visit as reported in the eCRF) up to 24 months
Time to therapy discontinuation due to AE >= grade 3 was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Avelumab Plus Axitinib Therapy Among Participants Who Discontinued the Axitinib Due to All-Cause AEs >= Grade 3
Ramy czasowe: Time from first dose of study drug up to 24 months
The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC. Duration of Avelumab plus Axitinib therapy (days) = (Date of discontinuation of Axitinib - Date of index date + 1). Duration of avelumab plus axitinib therapy among participants who discontinued the Axitinib due to all-cause AEs >= grade 3 was reported.
Time from first dose of study drug up to 24 months
Time to Onset of Treatment - Emergent Adverse Events (TEAEs)
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months
Time to onset of TEAE = Start date TEAE - Index date. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Treatment-Emergent Adverse Events (TEAEs)
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of TEAE = (Stop date of TEAE - Start date of TEAE + 1) divided by 7. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of Participants With Therapy Modifications Due to Adverse Event Related to Avelumab Plus Axitinib Therapy
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants with therapy modifications due to AE related to avelumab plus axitinib therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Number of Participants With Different Types of Medical Intervention or Medications Used for the Management of TEAEs Related to Avelumab Plus Axitinib Therapy
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Number of participants with different types of medical intervention or medications used for the management of TEAE related to avelumab plus axitinib therapy (e.g., use of corticosteroids, antihypertensive therapy, treatment for thyroid dysfunction, measures to decrease hemoglobin, and hematocrit) was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Percentage of Participants Receiving Later-line Therapy
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants receiving later-line therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Time to Second-line Therapy Initiation
Ramy czasowe: Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Time to second line treatment was calculated as: (second line treatment start date - last dose of Avelumab plus Axitinib + 1)/30.4375.
Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Number of Participants With Patient-reported Potential Signs and Symptoms of Immune-related AEs
Ramy czasowe: From index date (baseline visit as reported in the eCRF) up to 24 months
Number of participants with patient-reported potential signs and symptoms of immune-related AEs were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Współpracownicy

Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Śledczy

  • Dyrektor Studium: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 sierpnia 2021

Zakończenie podstawowe (Rzeczywisty)

8 sierpnia 2024

Ukończenie studiów (Rzeczywisty)

30 kwietnia 2025

Daty rejestracji na studia

Pierwszy przesłany

23 czerwca 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 czerwca 2021

Pierwszy wysłany (Rzeczywisty)

28 czerwca 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

20 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • MS100070_0110

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj